戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ) was synthesized for potential use in boron neutron capture therapy.
2 ntially could be used as delivery agents for neutron capture therapy.
3  boronated EGF to EGFR (+) gliomas for boron neutron capture therapy.
4  investigated as a potential agent for boron neutron capture therapy.
5 delivery and subsequent application in boron neutron capture therapy.
6 PA, and, subsequently, the efficacy of boron neutron capture therapy.
7 sting templates as carriers of 10B for boron neutron capture therapy.
8 e, nanomaterials, molecular electronics, and neutron capture therapy.
9 ototherapy, in addition to their promise for neutron capture therapy.
10 , inhibition of hydrolytic enzymes and boron neutron capture therapy.
11 e reactor poison(11) and a potential medical neutron capture therapy agent(12).
12 maging, and in carboranes that are potential neutron capture therapy agents as well as novel agents i
13 potential in traditional areas such as Boron Neutron Capture Therapy agents, but also as pharmacophor
14              Protons, neutrons, pions, boron-neutron capture therapy, and charged-nuclei therapy (wit
15 cleotides are potential candidates for boron neutron capture therapy, antisense technology, and as to
16 ufficient amounts of 10B for effective boron neutron capture therapy ( approximately 10(8)-10(9) 10B
17                                        Boron neutron capture therapy (BNCT) allows the selective elim
18                     The application of boron neutron capture therapy (BNCT) following liposomal deliv
19                                        Boron neutron capture therapy (BNCT) is a high-LET particle ra
20                                        Boron neutron capture therapy (BNCT) is a re-emerging binary c
21                             Success of boron neutron capture therapy (BNCT) is dependent on cellular
22                                        Boron neutron capture therapy (BNCT) is dependent on the selec
23                     The application of boron neutron capture therapy (BNCT) mediated by liposomes con
24 -yl] thymidine, designated N5-2OH, for boron neutron capture therapy (BNCT) of brain tumors using the
25                                        Boron neutron capture therapy (BNCT) using 4-[10B]boronophenyl
26                                        Boron neutron capture therapy (BNCT) was clinically approved i
27                                        Boron neutron capture therapy (BNCT), a binary treatment modal
28 to cancer cells for the application of boron neutron capture therapy (BNCT), a noninvasive approach t
29                                        Boron neutron capture therapy (BNCT), an experimental treatmen
30 as potential boron delivery agents for boron neutron capture therapy (BNCT).
31 on carriers historically evaluated for boron neutron capture therapy (BNCT).
32 cal applications, including photo- and boron neutron capture therapies, but the fabrication of non-to
33 e 2 was also tested as a candidate for boron neutron capture therapy, but showed poor tumor retention
34  exceptional challenge, because viable boron neutron-capture therapy by this method will require the
35 s to determine whether the efficacy of boron neutron capture therapy could be enhanced by means of in
36                       The viability of boron neutron capture therapy depends on the development of tu
37                     These studies with boron neutron capture therapy for CIA suggest that this form o
38 ylalanine has been applied in clinical boron neutron capture therapy for the treatment of high-grade
39  linked to epidermal growth factor (EGF) for neutron capture therapy in rats bearing a syngeneic epid
40 sign and synthesis of therapeutics for boron neutron capture therapy of cancer.
41  two clinically approved drugs used in boron neutron capture therapy of cancer.
42 gest that this agent may be useful for boron neutron capture therapy of cancer.
43 aining compounds that maybe useful for boron neutron capture therapy of tumors.
44 tein-based targeting strategies to the boron neutron-capture therapy of cancer poses an exceptional c
45                                        Boron neutron capture therapy represents a promising avenue fo
46 n these favorable in vitro and in vivo data, neutron capture therapy studies will be initiated using
47                     The application of boron neutron capture therapy to rheumatoid arthritis requires
48 on cluster system, previously used for boron neutron capture therapy, was modified by the addition of
49  boronated EGF as a delivery agent for boron neutron capture therapy, which is based on the capture r
50 nd proteins for further exploration in boron neutron capture therapy, which requires the targeted del
51 o a novel class of boron delivery agents for neutron capture therapy, which was designated 3-carboran